Celcuity, Inc. (NASDAQ:CELC) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: "Moderate Buy" — 12 analysts cover Celcuity (10 buys, 1 hold, 1 sell) with an average 12‑month price target of $134.50 and several firms recently raising targets.
• Major clinical catalyst: Topline Phase 3 VIKTORIA‑1 results showed the PIK3CA‑mutant cohort met its primary endpoint, prompting plans for a supplemental FDA filing and an ASCO presentation, and driving a ~15% jump in the stock.
• Risks and positioning: Insiders have recently sold shares while institutional ownership has risen (institutions ~63%), and the company remains unprofitable with notable leverage, posing execution and valuation risks despite the clinical upside.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $134.50.

Several equities research analysts have issued reports on CELC shares. Wolfe Research reaffirmed an "outperform" rating and set a $110.00 price target on shares of Celcuity in a research note on Thursday, March 12th. Guggenheim lifted their price target on Celcuity from $135.00 to $165.00 and gave the stock a "buy" rating in a research note on Monday. Citigroup reissued an "outperform" rating on shares of Celcuity in a research note on Monday. Craig Hallum reissued a "buy" rating and issued a $189.00 target price on shares of Celcuity in a research note on Monday. Finally, Wall Street Zen lowered Celcuity from a "hold" rating to a "sell" rating in a research note on Saturday, April 25th.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 3,000 shares of the business's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the sale, the director owned 6,760 shares of the company's stock, valued at approximately $745,425.20. The trade was a 30.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company's stock.

Institutional Investors Weigh In On Celcuity

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Celcuity by 23.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company's stock valued at $101,717,000 after purchasing an additional 391,262 shares during the period. New York State Common Retirement Fund increased its holdings in Celcuity by 68.0% during the 3rd quarter. New York State Common Retirement Fund now owns 47,704 shares of the company's stock valued at $2,357,000 after purchasing an additional 19,313 shares during the period. Atle Fund Management AB purchased a new position in Celcuity during the 3rd quarter valued at about $1,836,000. Candriam S.C.A. increased its holdings in Celcuity by 48.3% during the 3rd quarter. Candriam S.C.A. now owns 390,924 shares of the company's stock valued at $19,312,000 after purchasing an additional 127,348 shares during the period. Finally, Nisa Investment Advisors LLC increased its holdings in Celcuity by 2,142.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company's stock valued at $772,000 after purchasing an additional 14,930 shares during the period. Institutional investors own 63.33% of the company's stock.

Celcuity Trading Up 15.4%

Shares of CELC stock opened at $144.98 on Tuesday. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. The business has a 50-day moving average price of $114.53 and a two-hundred day moving average price of $102.64. Celcuity has a 12-month low of $9.51 and a 12-month high of $151.02. The firm has a market cap of $7.01 billion, a P/E ratio of -38.25 and a beta of 0.09.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.09. Equities analysts anticipate that Celcuity will post -3.97 EPS for the current fiscal year.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Topline Phase 3 VIKTORIA‑1 results reported that the PIK3CA‑mutant cohort met its primary endpoint (statistically significant, clinically meaningful PFS benefit); Celcuity plans a supplemental FDA filing and will present detailed data at ASCO, creating near‑term regulatory and commercial catalysts. QuiverQuant VIKTORIA-1 Topline
• Positive Sentiment: Independent coverage highlights that gedatolisib outperformed Novartis’ alpelisib (Piqray) in the Phase 3 comparisons reported, boosting gedatolisib’s competitive positioning in HR+/HER2‑ advanced breast cancer. FierceBiotech: Gedatolisib vs Piqray
• Positive Sentiment: Media pieces and company commentary say the VIKTORIA‑1 data strengthen Celcuity’s ASCO profile and commercial narrative for gedatolisib, increasing visibility among oncologists and investors. Yahoo Finance: ASCO Spotlight
• Positive Sentiment: Analysts raised price targets (Needham to $157, Citizens JMP to $160) and at least one analyst publicly speculated Celcuity could be an acquisition target after the new data — both actions can drive buying interest and multiple expansion. MSN: Analyst Raise / M&A Talk
• Neutral Sentiment: Celcuity already has an active regulatory pathway: the company previously announced FDA acceptance of an NDA for gedatolisib in the PIK3CA wild‑type HR+/HER2‑ population with a July PDUFA date — additional filings or approvals would be separate, incremental opportunities. ClinicalTrialsArena: VIKTORIA-1 Results
• Neutral Sentiment: Institutional ownership has grown substantially in recent quarters (large inflows from several funds), which can amplify moves on catalyst news but also increase volatility if positions are rotated. QuiverQuant: Institutional Activity
• Negative Sentiment: Insider activity shows recent insider sales (multiple officers sold shares over the past six months), which some investors read as a cautionary signal even if driven by diversification or liquidity needs. QuiverQuant: Insider Trades
• Negative Sentiment: Celcuity remains unprofitable (negative EPS) and has notable leverage metrics for a biotech; commercial execution and reimbursement, if approvals follow, will be key long‑term determinants of valuation.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.